Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background.: Treatment of multiple myeloma has changed significantly over the past several years with clinical trials reporting superior survival results using newer agents. Previous work has shown that the survival rate has improved for younger, but not older, patients with myeloma. Here, we update survival estimates for patients with myeloma in the early 21st century to determine whether continued improvement can be seen on a population level and whether or not it now extends to older patients. Methods.: Using period analysis to examine data from the Surveillance, Epidemiology, and End Results database, we estimate changes in the 5- and 10-year relative survival rates (RSRs) from 1998–2002 to 2003–2007. Results.: The 5- and 10-year RSRs have improved for patients with myeloma overall, from 32.8% and 15% in 1998–2002 to 40.3% and 20.8%, respectively, in 2003–2007. The greatest improvements were observed for patients aged 15–44 years, with 5- and 10-year RSRs reaching >70% and ∼50%, respectively, but improvements were also seen for patients aged >70 years. Conclusion.: Overall, survival continues to improve for patients with myeloma, including older patients, suggesting that newer treatment options continue to make a population-wide impact.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 1×
“Several unconventional agents, including the immunomodulators thalidomide [3] and lenalidomide [15] and the proteosome inhibitor bortezomib [4], have been shown to produce longer survival times in patients with MM in clinical trials.”
Background
Cited by
Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos-Gragera, R., Maynadié, M., Monnereau, A., Osca-Gelis, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70282-7 · Cited by 291
Self-citationPalumbo, A., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S., Waage, A., Larocca, A., van der Holt, B., Musto, P., Offidani, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70609-0 · Cited by 289
Association of response endpoints with survival outcomes in multiple myeloma
Lonial, S., & Anderson, K. C. (2014) · Leukemia · doi:10.1038/leu.2013.220 · Cited by 162
Bortezomib for the treatment of multiple myeloma
Scott, K., Hayden, P. J., Will, A., Wheatley, K., & Coyne, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010816.pub2 · Cited by 158
Rodríguez‐Lobato, L. G., Pereira, A., Fernández de Larrea, C., Cibeira, M. T., Tovar, N., Jiménez‐Segura, R., Moreno, D. F., Oliver‐Caldés, A., Rosiñol, L., & Bladé, J. (2022) · British Journal of Haematology · doi:10.1111/bjh.17888 · Cited by 19
Metadata
- Authors
- Pulte, D., Gondos, A., & Brenner, H.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-10-03
- Volume
- 16
- Issue
- 11
- Pages
- 1600-1603
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2099077086
- Cited by
- 144
- References
- 3
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data. https://app.cochat.ai/papers/10.1634/theoncologist.2011-0229
- The paper
- Pulte, D., Gondos, A., & Brenner, H. (2011). Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data. The Oncologist. https://doi.org/10.1634/theoncologist.2011-0229
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.